Printer Friendly

BAKER CUMMINS PHARMACEUTICALS RECEIVES LICENSE TO CHEMOPROTECTIVE DRUG

 BAKER CUMMINS PHARMACEUTICALS RECEIVES LICENSE
 TO CHEMOPROTECTIVE DRUG
 MIAMI, Feb. 5 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that its wholly owned subsidiary Baker Cummins Pharmaceuticals, Inc. received an exclusive worldwide license to a proprietary new drug for use in reducing toxicities associated with chemotherapy and radiation therapy. The drug was synthesized by Professor Michael Albeck of the Chemistry Dept. of Bar Ilan University and developed by Professor Benjamin Sredni, head of the Cancer, AIDS and Immunology Research Institute (CAIR) at Bar Ilan University.
 The drug is currently undergoing Phase II clinical studies in lung cancer patients in four centers in Israel. The clinical data indicates that the drug when used in combination with chemotherapeutic agents significantly reduces the hematologic toxicity associated with cancer chemotherapy. In these trials, patients receiving the drug in combination with chemotherapy experienced fewer life threatening reductions in platelets (thrombocytopenia) and neutrophils (neutropenia) than those patients receiving chemotherapy alone. The drug is thought to exert its chemoprotective effect by influencing various cytokines including interleukins (IL 1, 3 and 6 and colony stimulating factors CSFs).
 Baker Cummins Pharmaceuticals plans to begin clinical trials to study the chemoprotective effects of this drug in cancer patients in the United States. The company is also conducting studies in various animal models of human diseases to evaluate other potential uses for this drug.
 Dr. Phillip Frost, chairman of IVAX Corporation, said "The preliminary data developed for this drug are very impressive. Although considerable additional clinical testing must be performed, we are hopeful that if the data already obtained are confirmed, the drug will allow for more aggressive cancer treatment with fewer side effects."
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Best Generics, Inc., a national distributor of off-patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 2/5/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation ST: Florida IN: MTC SU:


SS-XX -- FL007 -- 7143 02/05/92 11:37 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:429
Previous Article:AORTECH INCLUDED ON LIST OF MARGINABLE SECURITIES
Next Article:DESPITE RECESSION, PHILADELPHIA ADVERTISING AGENCY STEPS UP SUPPORT OF CHARITABLE AND COMMUNITY ORGANIZATIONS
Topics:


Related Articles
REORGANIZATION OF BAKER CUMMINS DERMATOLOGICALS, INC.
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR TOLMETIN
IVAX' PHARMACEUTICAL SUBSIDIARY INITIATES UNITED STATES CLINICAL STUDIES FOR ALZENE(TM)
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
BAKER CUMMINS PHARMACEUTICALS CHANGES ITS NAME TO BAKER NORTON PHARMACEUTICALS
BAKER NORTON PHARMACEUTICALS RECEIVES LICENSE FROM RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO FOR NEW VASODILATOR THERAPY
BAKER NORTON PHARMACEUTICALS RECEIVES LICENSE FROM BOSTON UNIVERSITY FOR METHOD TO TREAT CERTAIN INVOLUNTARY MOVEMENT DISORDERS
IVAX ANNOUNCES THE APPROVAL OF ELMIRON(R) IN CANADA
Sumitomo Pharmaceuticals Licenses Class of DACH Platinum Compounds to Aronex Pharmaceuticals.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters